FDA allows BioNTech-MediLink ADC trial to resume with lower, safer doses

FDA allows BioNTech-MediLink ADC trial to resume with lower, safer doses

Submitted by admin on August 19, 2024 - 10:11am
Source: 
Fierce Biotech
News Tags: 
MediLink Therapeutics
BioNTech
clinical trials
antibody-drug conjugates
Headline: 
FDA allows BioNTech-MediLink ADC trial to resume with lower, safer doses
snippet: 

The FDA has allowed MediLink Therapeutics to restart a phase 1 trial of its BioNTech-partnered antibody-drug conjugate (ADC) that saw three fatalities after the companies confirmed that only lower doses will be used.

Do Not Allow Advertisers to Use My Personal information